The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

A new study from the Texas A&M University School of Public Health provides additional evidence that meditation using ...

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...

A compelling new study is building on a growing body of evidence showing a common exercise supplement used to build muscle ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...